pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·Jul 21·1 min read
save

EU releases AI Act transparency guidelines, affecting health-tech developers

Jul 21, 2026·read at raps ↗RegulatoryNeutral

The European Commission has published new guidelines to help providers and users of artificial intelligence systems meet the transparency obligations set out in the EU AI Act.

The document explains the required disclosures and provides examples of situations where exemptions may apply.

While the guidance is not limited to any sector, companies that incorporate AI into medical devices or digital health solutions will need to evaluate their compliance with the rules.

The aim is to clarify expectations and promote consistent implementation of the transparency requirements across the European Union.

source

This writeup was produced by pharmadog from original reporting by raps.

Original headline: “European Commission publishes guideline on transparency obligations under AI Act”

read at raps ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 3d agoThis Week at FDA: Foreign clinical trial scrutiny, botanical drugs, and an EUA declarationraps
  • 4d agoIndustry asks FDA to expand prior knowledge guidanceraps
  • 4d agoRecon: CBER official overruled Replimune melanoma drug rejection; AbbVie claims Phase 3 win for multiple myeloma drugraps
  • 4d agoEuro Roundup: UK government moves to modernize legislative framework for medicines and devicesraps
  • 5d agoEMA launches data sharing pilot to gain confidence in NAMs, reduce animal testingraps